Health News Archive - July 23, 2012
BOTHELL, Wash., July 23, 2012 /PRNewswire/ -- BioLife Solutions, Inc.
SAN DIEGO, July 23, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), a company developing the advanced-stage OncoSec Medical System
NEW YORK, July 23, 2012 /PRNewswire/ -- Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced
Families Travel to Washington to Ask Congress to Preserve Kids' Access ALEXANDRIA, Va., July 23, 2012 /PRNewswire-USNewswire/ -- As the fight around the constitutionality
ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO(TM), in the United States and Europe following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com
WASHINGTON, July 23, 2012 /PRNewswire/ -- Today, the MAC AIDS Fund announced the Care for Life Initiative --- a multi-year, public-private sector effort to address the intractable barriers
NEW YORK, July 23, 2012 /PRNewswire/ -- TOURNEAU, America's leading watch retailer, has announced its support of the fight against AIDS through a multi-level partnership with the (RED)(TM)
CLEVELAND, July 23, 2012 /PRNewswire/ -- "Because of who you are, who you know, and what you do, you are going to be able to reach hundreds of thousands, if not, millions of people.
CARLSBAD, Calif., July 23, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) has developed a complete rapid molecular
BRISBANE, Calif., July 23, 2012 /PRNewswire/ -- InterMune, Inc.